Promoting Biologics Drug Development in China at Lower Cost, Higher Speed, and Superior Quality with

Conference Vision

The biologics market is evolving with rapid development. In the past year, sales of biologics have increased to 70% among top 10 blockbusters. Caner immunotherapy, cell therapies and Ebola vaccines have made substantial progress.

However, with patent cliff for some top biologics in recent years, there’ll be around 10 biologics going off patent in the next four years and meantime it will unleash USD 60 billion market size for biosimilars. In 2015, EMA approved over 20 biosilimars and FDA also accepted filings from Sandoz which is biosimilar arm of Novartis. As the most important pharma market, biosimilar sector is one of focal points for China pharma industry. CFDA released long-awaited biosimilar guideline and new Chinese pharmacopeia in 2015 which brings unprecedented growth opportunities to China biologics industry.

In another market sector, immunotherapy such as the development of PD-1/PD-L1 is gaining popularity in recent years. Based on intelligence released by GBI, it is expected that global market size for immunotherapy will expand to 74 billion in 2022 taking up most majority share of cancer therapy.

Under this background, Biologics Innovation & Frontier Technology China Summit 2016 (BITF 2016) will be convened in Shanghai in September. The summit aims at being a premier international biopharma gathering in China for senior executives to exchange latest biologics innovation in the world and explore collaboration.

Nearly 200 senior executives, leading scholars & researchers, as well as veteran investors from a range of international and Chinese biopharmaceutical companies, research institutes, investment firms and government agencies, will attend the summit.

The international summit will provide you the opportunity to take home cutting edge strategies and case studies on emerging market access, regulatory guidelines, quality and safety, clinical development, bioprocess optimization, R&D technologies etc to allow you to further your research, keep abreast of your competitors and stay on top of the latest technology advancements in China, US and worldwide.

We cordially invite you to attend this international summit and discuss China’s promising future of biologics industry.

Who should attend

Targeted Industries 
● Biopharmaceuticals
● Biotechs 
● Academia/NGOs 
● Government authority 
● CROs and CMOs 
● Academics, Research Institutes 
● NGOs and Government 
● Bioprocessing technology and solution provider 
● Cell culture companies 
● Venture Capitalist and investors 
● Consulting and law firms

Targeted Job Titles 
President, Vice President and Chief Executives, Scientists, Directors, （Deputy）General Managers and Head of : 
● Research and Development 
● External research/Partnering, Alliance/Immunology 
● Business development 
● Biopharmaceutical research 
● Antibody discovery 
● Regulatory affairs 
● Preclinical/clinical research and development 
● Biosimilars 
● Licensing 
● Marketing 
● Chief technology officers 
● Process development 
● Manufacturing 
● External manufacturing/manfacturing network 
● Quality assurance/quality control 
● Technical operations 
● Cell culture